Emerging cardiovascular risk factors in end-stage renal disease

Journal of Nephrology

Volumn 15, Issue 2, 2002, Pages 205-208

  Yaqoob, Mohammed M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; C REACTIVE PROTEIN; CYANOCOBALAMIN; ERYTHROMYCIN; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; IMMUNOGLOBULIN A ANTIBODY; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PLACEBO; PYRIDOXINE; ROXITHROMYCIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLAMYDIASIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG COST; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY FAILURE; META ANALYSIS; MORTALITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEINURIA; RISK FACTOR; UREMIA; CHRONIC KIDNEY FAILURE; PATHOPHYSIOLOGY; REVIEW;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RISK FACTORS; HUMANS;

EID: 0035988295     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Atherosclerosis - An inflammatory disease
2. Intrinsic fibrinolytic capacity and systemic inflammation: Novel risk factors for arterial thrombotic disease
3. Fibrinogen and coronary risk
4. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial
5. Activated protein C resistance and the FV: R506Q mutation in a random population sample - Associations with cardiovascular risk factors and coagulation variables
6. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
7. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
8. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men
9. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
10. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
11. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
12. Higher membrane permeability predicts poorer patient survival
13. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
14. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
15. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
16. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study
17. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group
18. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study
19. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
20. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
21. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
22. Advanced glycosylation end products in patients with diabetic nephropathy
23. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
24. Hyperhomocysteinemia: An independent risk factor for vascular disease
25. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
26. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations